Baseline characteristics of the subjects
| Parameters | Total (n=74) | pHBP (n=56) | npHBP (n=18) | P values |
| Male | 43 (58.1%) | 32 (57.1%) | 11 (61.1%) | 0.767 |
| Age | 69.6±9.2 | 68.6±9.5 | 72.8±7.49 | 0.086 |
| Diabetes | 11 (14.9%) | 7 (12.5%) | 4 (22.2%) | 0.530 |
| Renal dysfunction | 11 (14.9%) | 8 (14.3%) | 3 (16.7%) | 0.894 |
| Hypertension | 34 (45.9%) | 23 (41.1%) | 11 (61.1%) | 0.138 |
| NICM | 63 (85.1%) | 46 (82.1%) | 17 (94.4%) | 0.371 |
| ICM | 6 (8.1%) | 6 (10.7%) | 0 (0%) | 0.341 |
| CAD | 28 (37.8%) | 21 (37.5%) | 7 (38.9%) | 0.916 |
| PCI | 9 (12.2%) | 7 (12.5%) | 2 (11.1%) | 0.797 |
| Arrhythmia | ||||
| Persistent AF | 14 (18.9%) | 13 (23.2%) | 1 (5.6%) | 0.187 |
| AV node ablation | 8 (10.8%) | 8 (14.3%) | 0 (0%) | 0.207 |
| Paroxysmal AF | 4 (5.4%) | 3 (5.4%) | 1 (5.6%) | 0.974 |
| AV block | 12 (16.2%) | 8 (14.3%) | 4 (22.2%) | 0.669 |
| Echocardiogram | ||||
| LVEF | 34.0±10.3 | 33.3±10.0 | 36.3±11.2 | 0.279 |
| LVESV | 125.8±55.1 | 127.0±57.8 | 122.4±45.5 | 0.763 |
| Medication | ||||
| Diuretic | 69 (93.2%) | 52 (92.9%) | 17 (94.4%) | 0.759 |
| β-Block | 57 (77.1%) | 45 (80.3%) | 12 (66.7%) | 0.379 |
| ACEI/ARB | 65 (87.8%) | 48 (85.7%) | 17 (94.4%) | 0.568 |
*P values, comparison between pHBP and npHBP.
ACEI, ACE inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; AV, atrioventricular; CAD, coronary artery disease; ICM, ischaemic cardiomyopathy; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MI, myocardial infarction; NICM, non-ischaemic cardiomyopathy; npHBP, non-permanent His bundle pacing; PCI, percutaneous coronary intervention; pHBP, permanent His bundle pacing.